Altimmune, Inc.

ALT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Assets
Cash & Equivalents $8.8M $2.9M $15.6M $18.6M $10.5M $12.7M $11.2M $11.8M
Accounts Receivable — — — $400.0K $3.6M — $4.9M $5.4M
Inventory — — — — — — — —
Total Current Assets $23.5M $4.5M $17.2M $19.3M $14.3M $19.8M $19.6M $23.6M
Property, Plant & Equipment $603.1K $177.9K $233.7K $325.8K $386.1K $484.0K $788.7K $1.2M
Goodwill — $18.8M $22.5M $2.3M $2.3M $2.3M $2.3M $2.3M
Intangible Assets (Excl. Goodwill) $38.7M $15.0M — — — — — —
Total Assets $63.0M $38.4M $19.9M $22.0M $17.1M $22.7M $22.8M $27.2M
Liabilities
Accounts Payable $129.1K $2.0M $521.1K $391.4K $1.1M $1.7M $1.4M $3.1M
Total Current Liabilities $3.8M $5.5M $2.2M $2.6M $6.8M $7.5M $4.6M $6.2M
Long-Term Debt $599.9K — — — $730.3K $1.7M — —
Total Liabilities $14.4M $6.2M $3.2M $3.7M $9.8M $11.1M $7.0M $15.0M
Stockholders' Equity
Retained Earnings $-77.7M $-31.3M $-223.7M $-220.3M $-210.3M $-198.6M $-193.7M $-189.9M
Total Stockholders' Equity $39.4M $32.2M $43.1M $18.3M $7.3M $11.7M $15.9M $12.2M
← Newer Page 2 of 2 Older →